News
Aavantgarde Bio Announces FDA Orphan Drug Designation For AAVB-081 For The Treatment Of Usher Syndrome Type 1B Retinitis Pigmentosa
(MENAFN - GlobeNewsWire - Nasdaq) MILAN, Dec. 02, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary ...
By: menafn
- Dec 02 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS